Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 16;14(6):e26008.
doi: 10.7759/cureus.26008. eCollection 2022 Jun.

Frequency of Specific and Non-specific Inhibitors in Haemophilia A Patients

Javeria Ashfaq  1 , Faryal Tariq  1 , Rehana Ahmed  2 , Warkha Thakur  2 , Madiha Abid  2 , Munira Borhany  2
Affiliations

Frequency of Specific and Non-specific Inhibitors in Haemophilia A Patients

Javeria Ashfaq et al. Cureus. .

Abstract

Objective: To determine the frequency of specific and non-specific inhibitors in haemophilia A patients.

Study design: This is a cross-sectional study.

Patients and methods: A total of 150 male haemophilia A patients were included in this cross-sectional study at the National Institute of Blood Diseases and Bone Marrow Transplant (NIBD), Karachi, Pakistan, from September 2019 to January 2022.

Results: Among 150 patients included in this study, 23 (15.3%) had an inhibitor and 127 (84.6%) did not. All patients had specific inhibitors against Factor VIII (FVIII). Non-specific inhibitors were not identified in our population. Among the patients in the inhibitor group, there were 13 (56.5%) in the severe (<1%) category. There were 10 (43.5%) patients in the moderate (1-5%) category. There were no patients in the mild category. The median inhibitor level was 15.4 Bethesda unit (BU).

Conclusion: The development of inhibitors has not been identified as a major problem in our population. However, it is noteworthy that only 15.3% of patients with haemophilia A developed inhibitors in this data set. They were essentially treated with plasma and its products.

Keywords: factor viii inhibitors; factor viii; fviii; non specific inhibitors; plasma; s: haemophilia complications.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Frequency of bleeding in haemophilia A patients in the study
See this image and copyright information in PMC

References

    1. The molecular genetic analysis of hemophilia A: a directed search strategy for the detection of point mutations in the human factor VIII gene. Pattinson J, Millar DS, McVey J, et al. 1990;76:2242–2248. - PubMed
    1. Hemophilia treatment in historical perspective: a review of medical and social developments. Rosendaal FR, Smit C, Briët E. https://pubmed.ncbi.nlm.nih.gov/1903310/ Ann Hematol. 1991;62:5–15. - PubMed
    1. Development of inhibitors in patients with haemophilia from India. Ghosh K, Shetty S, Kulkarni B, et al. Haemophilia. 2001;7:273–278. - PubMed
    1. Frequency of factor VIII (FVIII) inhibitor in haemophilia A. Borhany M, Kumari M, Shamsi T, Naz A, Farzana T. https://pubmed.ncbi.nlm.nih.gov/22538032/ J Coll Physicians Surg Pak. 2012;22:289–293. - PubMed
    1. Frequency and levels of factor eight inhibitors in known haemophiliacs. Amir M, Hassan ZU, Aziz OBA, Ali N, Ahmad SQ. https://www.pafmj.org/index.php/PAFMJ/article/view/17 PAFMJ. 2018;68:712–716.

LinkOut - more resources